About This Fund
Atlas Venture Opportunity Fund III is the third dedicated follow-on capital vehicle of Atlas Venture, designed to provide longitudinal support to the firm's existing portfolio of biotechnology companies as they advance through later stages of clinical and commercial development. Unlike the firm's flagship early-stage funds, which focus on founding and seeding new biotechnology startups, the Opportunity Fund series is specifically engineered to allow Atlas to increase ownership stakes in its most promising portfolio companies as they raise subsequent financings, advance clinical programs, and approach potential liquidity events. Atlas Venture has been operating at the intersection of early-stage biotechnology and venture creation since the early 1990s, with a portfolio spanning drug discovery, cell and gene therapy, clinical-stage biopharmaceuticals, and medical device innovation.
The fund enables Atlas Venture to write individual checks of up to USD 20 to USD 25 million per investment, directed toward both privately held portfolio companies raising Series B and later rounds and publicly traded portfolio companies conducting secondary offerings or structured transactions. This flexibility allows Atlas to support portfolio companies at critical financing milestones regardless of their public or private status, reinforcing the firm's long-term commitment to each company and its founders through the full investment lifecycle. The general partners managing Opportunity Fund III are Kevin Bitterman, Bruce Booth, Michael Gladstone, and Jason Rhodes.
Atlas Venture Opportunity Fund III closed at USD 400 million on September 4, 2025, in an oversubscribed fundraise — the third time Atlas has raised such a vehicle, following a USD 300 million predecessor closed in 2021. The fund was raised closely on the heels of Atlas Venture Fund XIV, the firm's USD 450 million fourteenth early-stage fund closed in December 2024, underscoring the breadth and depth of investor conviction in the Atlas Venture platform. Together, the two vehicles give Atlas more than USD 850 million in fresh capital to deploy across new company creation and portfolio support, establishing Atlas as one of the most active and well-capitalized biotech venture platforms in the United States.